The CAD-detTM System is a rapid, non-invasive test designed to increase the standard of care for detection of CAD, while decreasing costs and enhancing patient safety.
In just a few minutes, the CAD-det System uses its patented technology to acquire and analyze cardiac acoustic data (an “AusculCardiogramTM”) and is designed to deliver immediate results with high diagnostic accuracy, potentially enabling clinicians to rule-out CAD in patients while ensuring at-risk patients receive the proper level of care.
Potential Benefits to Patients:
- Test is completed in minutes.
- No exposure to radiation.
- No exercise or pharmaceutical stress required.
Potential Benefits For Healthcare Professionals:
- Easy for physicians, nurses, and technicians to use.
- Short test times, with immediate results.
- Novel data presentation for aiding clinical decision-making.
- Integration with health record systems.
- Suitable for busy hospitals and clinics.
The CAD-det System has been authorized by Health Canada for investigational use only, and is expected to be available for commercial sale in 2021.
The Medical Issue
Coronary Artery Disease (“CAD”)
- The leading cause of premature death worldwide, accounting for more deaths than all cancers combined.
- Predicted to increase 18% by 2030 due to patient obesity, stress due to lifestyle factors, and aging populations1.
Detection is a substantial challenge:
- Only 20% of CAD cases are diagnosed prior to a heart attack2.
- In 57% of cases, sudden cardiac death is the first symptom3.
Lifetime risk of developing CAD after age 401
The % of Sudden Cardiac Deaths where patients were previously asymptomatic
Diagnostic Accuracy of Exercise Stress Test
Current Diagnostics Have Limitations and Risks
- Coronary Computed Tomography Angiography (CCTA) and Invasive Coronary Angiography (ICA) have high diagnostic accuracy, but are cost prohibitive for widespread use, and expose patients to the equivalent of between 3.8 and 7.7 years of background radiation.
- First line diagnostics such as exercise treadmill test are lower cost, but lack sufficient diagnostic accuracy, resulting in unnecessary referrals to CCTA and ICA.
- Between 25% and 50% of patients receiving CCTA and ICA procedures have no obstructive CAD
Lack of an accurate, cost-effective, and patient-friendly modality for CAD detection has resulted in:
- High costs for payors.
- Diagnostic challenges for physicians.
- Adverse outcomes and inconvenience for patients.